TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 EUROPE FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 EUROPE 99
15.1.1 GERMANY 106
15.1.2 FRANCE 108
15.1.3 U.K. 110
15.1.4 ITALY 112
15.1.5 SPAIN 114
15.1.6 RUSSIA 116
15.1.7 TURKEY 118
15.1.8 NETHERLANDS 120
15.1.9 SWITZERLAND 122
15.1.10 HUNGARY 124
15.1.11 LITHUANIA 126
15.1.12 AUSTRIA 128
15.1.13 IRELAND 130
15.1.14 NORWAY 132
15.1.15 POLAND 134
15.1.16 REST OF EUROPE 136
16 EUROPE FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 137
16.1 COMPANY SHARE ANALYSIS: EUROPE 137
17 SWOT ANALYSIS 138
18 COMPANY PROFILE 139
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 139
18.1.1 COMPANY SNAPSHOT 139
18.1.2 REVENUE ANALYSIS 139
18.1.3 COMPANY SHARE ANALYSIS 140
18.1.4 PRODUCT PORTFOLIO 140
18.1.5 RECENT DEVELOPMENTS 140
18.2 GENENTECH, INC. 141
18.2.1 COMPANY SNAPSHOT 141
18.2.2 COMPANY SHARE ANALYSIS 141
18.2.3 PRODUCT PORTFOLIO 142
18.2.4 RECENT DEVELOPMENTS 142
18.3 SANDOZ INTERNATIONAL GMBH 143
18.3.1 COMPANY SNAPSHOT 143
18.3.2 COMPANY SHARE ANALYSIS 143
18.3.3 PRODUCT PORTFOLIO 144
18.3.4 RECENT DEVELOPMENTS 144
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 145
18.4.1 COMPANY SNAPSHOT 145
18.4.2 REVENUE ANALYSIS 145
18.4.3 COMPANY SHARE ANALYSIS 146
18.4.4 PRODUCT PORTFOLIO 146
18.4.5 RECENT DEVELOPMENTS 146
18.5 ACCORD HEALTHCARE U.S. 147
18.5.1 COMPANY SNAPSHOT 147
18.5.2 COMPANY SHARE ANALYSIS 147
18.5.3 PRODUCT PORTFOLIO 148
18.5.4 RECENT DEVELOPMENTS 148
18.6 ABBVIE INC. 149
18.6.1 COMPANY SNAPSHOT 149
18.6.2 REVENUE ANALYSIS 149
18.6.3 PRODUCT PORTFOLIO 150
18.6.4 RECENT DEVELOPMENTS 150
18.7 ALPINE IMMUNE SCIENCES 151
18.7.1 COMPANY SNAPSHOT 151
18.7.2 REVENUE ANALYSIS 151
18.7.3 PRODUCT PORTFOLIO 152
18.7.4 RECENT DEVELOPMENTS 152
18.8 BELLBROOK LABS 153
18.8.1 COMPANY SNAPSHOT 153
18.8.2 PRODUCT PORTFOLIO 153
18.8.3 RECENT DEVELOPMENTS 153
18.9 BIOMX 154
18.9.1 COMPANY SNAPSHOT 154
18.9.2 REVENUE ANALYSIS 154
18.9.3 PRODUCT PORTFOLIO 155
18.9.4 RECENT DEVELOPMENTS 155
18.10 BRISTOL-MYERS SQUIBB COMPANY 156
18.10.1 COMPANY SNAPSHOT 156
18.10.2 REVENUE ANALYSIS 156
18.10.3 PRODUCT PORTFOLIO 157
18.10.4 RECENT DEVELOPMENTS 157
18.11 CAMBER PHARMACEUTICALS, INC. 158
18.11.1 COMPANY SNAPSHOT 158
18.11.2 PRODUCT PORTFOLIO 158
18.11.3 RECENT DEVELOPMENTS 158
18.12 ENVEDA 159
18.12.1 COMPANY SNAPSHOT 159
18.12.2 PRODUCT PORTFOLIO 159
18.12.3 RECENT DEVELOPMENTS 159
18.13 GILEAD SCIENCES, INC. 160
18.13.1 COMPANY SNAPSHOT 160
18.13.2 REVENUE ANALYSIS 160
18.13.3 PRODUCT PORTFOLIO 161
18.13.4 RECENT DEVELOPMENTS 161
18.14 INTERCEPT PHARMACEUTICALS, INC. 162
18.14.1 COMPANY SNAPSHOT 162
18.14.2 REVENUE ANALYSIS 162
18.14.3 PRODUCT PORTFOLIO 163
18.14.4 RECENT DEVELOPMENTS 163
18.15 KITHER BIOTECH S.R.L. 164
18.15.1 COMPANY SNAPSHOT 164
18.15.2 PRODUCT PORTFOLIO 164
18.15.3 RECENT DEVELOPMENTS 164
18.16 PHARMAXIS LTD 165
18.16.1 COMPANY SNAPSHOT 165
18.16.2 REVENUE ANALYSIS 165
18.16.3 PRODUCT PORTFOLIO 166
18.16.4 RECENT DEVELOPMENTS 166
18.17 REDX PHARMA PLC. 167
18.17.1 COMPANY SNAPSHOT 167
18.17.2 REVENUE ANALYSIS 167
18.17.3 PRODUCT PORTFOLIO 168
18.17.4 RECENT DEVELOPMENTS 168
18.18 VERONA PHARMA PLC 169
18.18.1 COMPANY SNAPSHOT 169
18.18.2 REVENUE ANALYSIS 169
18.18.3 PRODUCT PORTFOLIO 170
18.18.4 RECENT DEVELOPMENTS 170
19 QUESTIONNAIRE 171
20 RELATED REPORTS 174

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.